Insmed Inc (INSM)vsInnate Pharma (IPHA)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
IPHA
Innate Pharma
$1.26
-8.03%
HEALTHCARE · Cap: $110.60M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 4699% more annual revenue ($606.42M vs $12.64M). IPHA leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
IPHA
Avoid11
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 21.0x book value
ROE of -2.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : IPHA
IPHA has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : IPHA
The primary concerns for IPHA are Market Cap, Profit Margin, Price/Book. Debt-to-equity of 5.25 is elevated, increasing financial risk.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while IPHA is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
IPHA generates stronger free cash flow (-31M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 11/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Innate Pharma
HEALTHCARE · BIOTECHNOLOGY · USA
Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France and internationally. The company is headquartered in Marseille, France.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?